PACB:NSD-Pacific Biosciences of California (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 8.79

Change

0.00 (0.00)%

Market Cap

USD 1.98B

Volume

0.02B

Avg Analyst Target

USD 15.57 (+77.15%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


PACB Stock Forecast & Price:
Based on the Pacific Biosciences of California stock forecasts from 5 analysts, the average analyst target price for Pacific Biosciences of California is USD 15.57 over the next 12 months. Pacific Biosciences of California’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Pacific Biosciences of California is Bearish, which is based on 2 positive signals and 7 negative signals. At the last closing, Pacific Biosciences of California’s stock price was USD 8.79. Pacific Biosciences of California’s stock price has changed by +45.05% over the past week, +90.05% over the past month and -70.17% over the last year.

About Pacific Biosciences of California (PACB:NSD)

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including sing ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-08-14 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
DXCM DexCom Inc

N/A

USD35.00B 208.91 88.90
ALGN Align Technology Inc

N/A

USD22.57B 36.86 22.02
PODD Insulet Corporation

N/A

USD18.79B 510.75 127.76
LVGO Livongo Health, Inc

N/A

USD14.20B N/A N/A
ABMD ABIOMED Inc

N/A

USD13.35B 61.16 43.54
SWAV Shockwave Medical Inc

N/A

USD10.39B 191.48 154.91
BRKR Bruker Corporation

N/A

USD9.16B 34.34 19.15
IART Integra LifeSciences Holdings

N/A

USD4.69B 27.95 16.47
IRTC iRhythm Technologies Inc

N/A

USD4.55B N/A -39.96
WMGI Wright Medical Group N.V

N/A

USD3.90B N/A 50.67

ETFs Containing PACB

Symbol Name Weight Mer Price(Change) Market Cap

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -57.04% 17% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -57.04% 17% F 18% F
Trailing 12 Months  
Capital Gain -70.17% 23% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -70.17% 23% F 17% F
Trailing 5 Years  
Capital Gain 106.82% 81% B- 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 106.82% 81% B- 79% C+
Average Annual (5 Year Horizon)  
Capital Gain 156.28% 95% A 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 156.28% 95% A 96% A
Risk Return Profile  
Volatility (Standard Deviation) 287.32% 8% F 4% F
Risk Adjusted Return 54.39% 88% B+ 85% B
Market Capitalization 1.98B 85% B 78% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 194.47 19% F 6% F
Price/Book Ratio 2.62 55% F 36% F
Price / Cash Flow Ratio -17.78 84% B 81% B-
EV/EBITDA -6.81 75% C 81% B-
Management Effectiveness  
Return on Equity -43.76% 44% F 26% F
Return on Invested Capital -11.55% 59% F 36% F
Return on Assets -10.36% 55% F 31% F
Debt to Equity Ratio 113.28% 20% F 19% F
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 6.31 36% F 28% F
Short Percent 20.14% 3% F 8% F
Beta 1.43 37% F 27% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector